Phase III Study of Mitoxantrone Plus Low Dose Prednisone Versus Low Dose Prednisone Alone in Patients With Asymptomatic Hormone Refractory Prostate Cancer
- 1 December 2002
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 168 (6) , 2439-2443
- https://doi.org/10.1016/s0022-5347(05)64163-8
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780Journal of Clinical Oncology, 2001
- PROSTATE SPECIFIC ANTIGEN RESPONSE TO MITOXANTRONE AND PREDNISONE IN PATIENTS WITH REFRACTORY PROSTATE CANCER: PROGNOSTIC FACTORS AND GENERALIZABILITY OF A MULTICENTER TRIAL TO CLINICAL PRACTICEJournal of Urology, 2000
- Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 StudyJournal of Clinical Oncology, 1999
- Health-Related Quality of Life in Men With Metastatic Prostate Cancer Treated With Prednisone Alone or Mitoxantrone and PrednisoneJournal of Clinical Oncology, 1999
- CHEMOTHERAPY FOR HORMONE REFRACTORY PROSTATE CANCERUrologic Clinics of North America, 1999
- MitoxantroneDrugs & Aging, 1997
- Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.Journal of Clinical Oncology, 1996
- Oral etoposide in the treatment of hormone-refractory prostate cancerCancer, 1994
- Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the eastern cooperative oncology groupCancer, 1993
- MitoxantroneDrug Intelligence & Clinical Pharmacy, 1986